Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.
The study reveals the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.
The initiative aims to elevate the professional capabilities of pharmacy technicians and foster leadership qualities essential for advancing in their careers.
Alvimopan Capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.
